Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells

用于表征循环肿瘤细胞的多相微流体装置

• 批准号: 8658772
• 负责人: John Zhong
• 金额: $ 9.92万
• 依托单位: UNIVERSITY OF SOUTHERN CALIFORNIA
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-05-01 至 2017-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8658772
• 关键词: Affect; Biochemical; Biological; Biological Models; Bioreactors; Blood; Breast Cancer Cell; Breast Cancer Treatment; Cancer Patient; Cell Separation; Cells; Characteristics; Clinical; Colorectal Cancer; Complementary DNA; Cytolysis; Development; Devices; Diagnostic Procedure; Disease Progression; Docking; ERBB2 gene; Electrodes; Encapsulated; Evaluation; FDA approved; Fluorescence; Flushing; Gene Amplification; Gene Expression; Gene Expression Profile; Gene Expression Profiling; Grant; Hela Cells; Heterogeneity; Hospitals; Individual; Laboratories; Malignant Neoplasms; Malignant neoplasm of prostate; Medicine; Microfluidic Microchips; Microfluidics; Molecular; Molecular Analysis; Molecular Profiling; Monitor; Mutation; Neoplasm Circulating Cells; Neoplasm Metastasis; Oils; Optics; Patients; Phase; Physicians; Prevalence; Primary Neoplasm; Process; Reverse Transcription; System; Technology; Testing; Trastuzumab; Travel; United States Food and Drug Administration; base; cancer diagnosis; cancer therapy; cell analyzer; clinical application; design; insight; malignant breast neoplasm; nanolitre; novel; operation; outcome forecast; prototype; success; tool; tumorigenesis

DESCRIPTION (provided by applicant): Multi-phase Microfluidic Devices for Characterization of Circulating Tumor Cells in Breast Cancer Oncogenesis is a multi-step process leading to a variety of genetic changes with alterations in the transcriptome, and adaptive changes responding to treatments. Therefore, monitoring the dynamic alteration of cancer is critical for cancer treatment. We have integrated multiple microfluidic modules developed in our R21 into a Multi-Phase Single Cell Analyzer (MSCA) for circulating tumor cells (CTC) enumeration and single CTC characterization. Combining the robustness of microstructure, preciseness of optical manipulation and mobility of droplet, the integrated MSCA isolates and encapsulates individual CTC into droplets for nanoliter molecular analysis. With the ability to characterize CTC in routine blood draws, the integrated platform will transform the minimal invasive CTC assessment into a powerful tool for cancer treatment evaluation in hospitals and clinical laboratories, and realize personalized medicine for cancer treatment.

描述（由申请人提供）：用于表征乳腺癌中循环肿瘤细胞的多相微流体装置肿瘤发生是一个多步骤过程，导致各种遗传变化，包括转录组的改变和对治疗的适应性变化。因此，监测癌症的动态变化对于癌症治疗至关重要。我们将R21中开发的多个微流控模块集成到多相单细胞分析仪（MSCA）中，用于循环肿瘤细胞（CTC）计数和单个CTC表征。集成的MSCA结合了微结构的鲁棒性、光学操作的精确性和液滴的流动性，将单个CTC分离并封装到液滴中用于纳升分子分析。具有在常规中表征CTC的能力 该集成平台将把微创CTC评估转化为医院和临床实验室癌症治疗评估的有力工具，实现癌症治疗的个性化用药。